Achillion Announces Initiation of ACH-3422 Dosing in HCV-Infected Patients and Ability to Resume Sovaprevir Clinical Program for the Treatment of Chronic HCV
June 10, 2014Achillion announced they have started dosing with nucleotide polymerase inhibitor ACH-3422 in their Phase 1 trial in HCV patients. In addition, the FDA removed the hold on the NS3/4A protease inhibitor sovaprevir, to permit future clinical trials.
More »
Celator® Pharmaceuticals Reaches 75% Enrollment Milestone in Phase 3 Study of CPX-351
June 4, 2014Celator® Pharmaceuticals announces 75% achievement of enrollment for its ongoing Phase 3 clinical study in which they are comparing CPX-551 to the conventional cytarabine and daunorubicin treatment in patients with high-risk acute myeloid leukemia (AML).
More »
NEW ENGLAND JOURNAL OF MEDICINE PUBLISHES DATA FROM DURATA THERAPEUTICS’ DISCOVER PROGRAM
June 4, 2014The New England Journal of Medicine published the Phase 3 data from Durata Therapeutic’s DISCOVER program. This program currently evaluates dalbavancin for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI).
More »